Hydralazine target: from blood vessels to the epigenome. - Wikidata - awgldk - TriplyDB

Hydralazine target: from blood vessels to the epigenome.

Hydralazine target: from blood vessels to the epigenome.

http://www.wikidata.org/entity/Q43251030

about

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid Novel epigenetic-based therapies useful in cardiovascular medicine Clinical applications of epigenetics in cardiovascular disease: the long road ahead The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series)Epigenetic modulators as therapeutic targets in prostate cancer A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.Radiosensitizers in cervical cancer. Cisplatin and beyond.Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA.Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study Vasomodulation of tumor blood flow: effect on perfusion and thermal ablation size Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.DNA cleavage and detection of DNA radicals formed from hydralazine and copper (II) by ESR and immuno-spin trapping.Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?The prince and the pauper. A tale of anticancer targeted agents.Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.Perspectives on epigenetics and its relevance to adverse drug reactions.Epigenetic-based therapies in cancer: progress to date.Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor.DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes.Radiofrequency ablation: post-ablation assessment using CT perfusion with pharmacological modulation in a rat subcutaneous tumor model.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury.Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine.Ensemble-Based Virtual Screening and Experimental Validation of Inhibitors Targeting a Novel Site of Human DNMT1.Targeting DNA Methyltranferases in Urological Tumors.DNA Methyltransferase Inhibitors

P2860

Q24288944-B20CA229-7CA9-45D1-A722-E9910FF2C86A Q26765152-CB489CA0-A5BB-4A9D-BC99-DA0AA1BB0966 Q27008290-8F6CBBA9-AFFF-4F5C-9F09-6825E9A934ED Q28069443-221679E5-9E6C-4EF1-A305-C9DB1F5500C6 Q28071912-7B57D369-1B29-4AC6-961C-31F2C5F37EE2 Q34142430-395A264B-C443-44BB-9E5F-63EC3B8A45C7 Q34684307-316203F4-1FCC-4370-BB66-B558F4C62E06 Q34724245-12706471-E743-43A9-8851-D160A9055488 Q35110633-8908FACC-AD63-419F-81E6-6F4B14D89F0E Q35674823-CFC42698-BB06-440A-AA21-5767EA18C738 Q35804140-E2947B7E-D83F-4712-ADEB-BF4C70AB0E04 Q36801625-088EC8A2-2ED0-4898-A111-FC7DAA5841F9 Q36960601-39427BC9-0CFC-4F20-B461-45A13853A521 Q37025333-28E9EA70-C5CD-4845-898A-F101498B61BD Q37042365-881C14F4-0D04-41C1-A2DE-C2EBE14F8988 Q37313424-90C0A4D3-9993-4DB1-8105-8A86529F8F6C Q37867482-9926FDA7-E88F-4335-A9CE-F25282DE27E9 Q37964702-ECB84E81-56A4-48C2-ACA1-5932155EF792 Q38011287-0D50DAB7-8940-4FF2-BA48-8653D8A3C979 Q38049175-26408B66-3AD3-4E42-89AA-DC74031E5E53 Q39508627-CA617770-23E3-439C-BF8D-67C8157FD047 Q39886168-DD2AC24F-352D-4A5E-988C-80A1DA03096C Q40996500-67997C44-102F-467C-9C03-CE20C0538565 Q42154363-2E1B62C5-CFD6-4125-99A5-CBA897283624 Q43150766-53B22E60-EDDC-4C82-8FD1-67D9ED1E35DA Q53185257-0A19C13E-4540-4CA8-9CA5-3B17A350D413 Q55435258-BD7C94DD-85BC-4747-AD98-4F5FCB916AE3 Q58860107-B7EBAD92-B01B-4883-AC00-442EEB9DB787

P2860

Hydralazine target: from blood vessels to the epigenome.

http://www.wikidata.org/entity/Q43251030

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Hydralazine target: from blood vessels to the epigenome.

@en

Hydralazine target: from blood vessels to the epigenome.

@nl

type

label

Hydralazine target: from blood vessels to the epigenome.

@en

Hydralazine target: from blood vessels to the epigenome.

@nl

prefLabel

Hydralazine target: from blood vessels to the epigenome.

@en

Hydralazine target: from blood vessels to the epigenome.

@nl

P1433

Q43251030-E5C66E62-9A28-42E1-BDA9-20E6D18D21B9

P1476

Q43251030-6C6D5615-3942-4F8A-9134-64741090B506

P2093

Q43251030-20E8A0E2-AD2E-4B9B-B569-9041BC810D2E

Q43251030-998C2654-2D50-4BEC-9BCC-08D4A4EE2210

Q43251030-C664D5D5-FB08-44AF-8892-004CC17F0FC4

Q43251030-CB8837ED-8EF0-4D41-9531-A4780BEE554C

Q43251030-FDEF8F8B-CFB8-4004-BB9E-810F895267D9

Q43251030-FFFFDDA0-0347-4F48-8F6D-7507F0500A73

P2860

Q43251030-0007CCBD-245B-4F18-9706-68200429A631

Q43251030-04F44C2C-D233-4810-A764-363C9D7A799B

Q43251030-05DEAD7D-3089-40DF-8A78-6B386AFE7316

Q43251030-07E5AB88-5CD0-4C32-A3A9-A75DDFB2ED15

Q43251030-0D25387A-9C86-4786-A0CF-CD86C1A9A077

Q43251030-0F97ED28-F55E-4475-A4C3-289E6911C008

Q43251030-11EFC7CC-CA59-4847-AD6B-B04F7D56AB3B

Q43251030-1215CFE2-89E4-4135-BA52-F04AA1398B85

Q43251030-13A4DD48-7DF9-4FB2-9396-FBFDF9504D5F

Q43251030-1C71592E-0DA1-4B95-8C38-1D4D181A50EA

P2888

Q43251030-CE782407-D28E-4A89-B693-D21B0EF6443D

P304

Q43251030-89A825BE-5C98-4CEE-B695-02C3DD30D457

P31

Q43251030-C9001F70-4140-4E5E-BB41-7B25F3871FC6

P356

Q43251030-F4AAA93E-9E64-40E3-B66C-D8FFB29654E8

P478

Q43251030-28D1923D-1330-450C-A1F6-C2450150314C

P577

Q43251030-8ECBACBD-B655-4F9F-BFAC-A5DEBA8EE49D

P5875

Q43251030-90116760-3C4E-449D-9A67-0B61443D3FF0

P6179

Q43251030-319C30C1-31E6-4A1E-8A17-59136135549D

P698

Q43251030-EA1270F5-D90B-4565-AEFF-19069FDBB639

P932

Q43251030-A4950C4A-2969-4C20-A036-FDA6E3FF70F9

P356

P1433

Journal of Translational Medicine

P1476

Hydralazine target: from blood vessels to the epigenome.

@en

P2093

Alfonso Dueñnas-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Blanca Segura-Pacheco

http://www.w3.org/2001/XMLSchema#string

Claudia Arce

http://www.w3.org/2001/XMLSchema#string

Enrique Perez-Cardenas

http://www.w3.org/2001/XMLSchema#string

Lucia Taja-Chayeb

http://www.w3.org/2001/XMLSchema#string

Myrna Candelaria

http://www.w3.org/2001/XMLSchema#string

P2860

The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors

DNA methylation patterns and epigenetic memory

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Epigenetics of cervical cancer. An overview and therapeutic perspectives

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

CpG-rich islands and the function of DNA methylation

Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?

Epigenetic reprogramming in mammalian development

P2888

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-4-10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7270863

http://www.w3.org/2001/XMLSchema#string

P6179

1005932401

http://www.w3.org/2001/XMLSchema#string

P698

16507100

http://www.w3.org/2001/XMLSchema#string

P932

1413557

http://www.w3.org/2001/XMLSchema#string